Collegium’s Pain Sales Fall 18% As ADHD Growth Leaves Earnings Behind
Jornay PM sales grew 24%, but operating expenses rose faster and Collegium kept its annual forecasts unchanged.
Collegium Pharmaceutical, which sells prescription ADHD and pain medicines, reported an 18% decline in third-quarter pain sales Thursday, even as its expanding ADHD business helped revenue reach a record $216.3 million. Revenue rose 3% from $209.4 million a year earlier, but both reported and adjusted earnings fell, according to the earnings release accompanying its SEC filing.
Higher Sales, Lower Earnings
Operating expenses reached $96.7 million, a 44% increase from $67.1 million a year earlier. Even after Collegium’s adjustments, expenses rose 25%, to $69.4 million from $55.7 million.
The earnings release put net income at $21.8 million, compared with $31.5 million a year earlier. Diluted earnings per share dropped from $0.84 to $0.60; adjusted earnings were $1.96 per share on $75.2 million of net income, versus $2.25 and $87.3 million.
Adjusted earnings before interest, taxes, depreciation and amortization fell 9%, to $121.6 million from $133.0 million. COLL shares fell about 3% to $24.40 in Friday trading.
ADHD Expands, Pain Contracts
Jornay PM delivered $51.9 million in sales, up 24% year-over-year. Prescription volume rose 16%, while its prescriber base grew 19% to nearly 33,000, a record for the medicine.
Vikram Karnani, Collegium’s president and chief executive officer, attributed ADHD demand to “expanded commercial efforts heading into the back-to-school season.” Azstarys added $26.5 million in its first full quarter under Collegium ownership, with prescriptions increasing nearly 2% year-over-year after declining in 2025.
The ADHD expansion rests on acquisitions. The 2024 Ironshore purchase brought Jornay PM and a sales team focused on neuropsychiatry and pediatrics; Collegium added Azstarys in May 2026, using its existing commercial infrastructure. Chief Financial Officer Colleen Tupper said ADHD now accounts for more than 36% of revenue.
Pain medicines still generated $138.0 million. Belbuca sales slipped 1% to $57.7 million, Xtampza ER fell 9% to $45.8 million, and the Nucynta franchise dropped 44% to $30.8 million. Nucynta’s total included $4.2 million from Hikma Pharmaceuticals USA for authorized generic versions of Nucynta and Nucynta ER.
Forecasts Hold, Buyback Settlement Ahead
Collegium retained its 2026 revenue outlook of $825 million to $855 million, including $190 million to $200 million for Jornay PM and $65 million to $75 million for Azstarys. Its forecast for adjusted earnings before interest, taxes, depreciation and amortization also stayed at $445 million to $470 million.
Operations generated $86.5 million in cash during the quarter. Collegium ended the period with $144.8 million in cash, cash equivalents and marketable securities.
Capital returns remain part of the plan. Collegium’s earnings presentation describes a $50 million buyback announced during the third quarter, structured as an accelerated share repurchase.
Collegium expects final settlement of that previously announced repurchase in the fourth quarter of 2026.
Sources
- 8-K Filing — COLLEGIUM PHARMACEUTICAL, INC (COLL) — SEC EDGAR
- Exhibit coll-2026x09x30xex99x1.htm — COLLEGIUM PHARMACEUTICAL, INC 8-K exhibit — SEC EDGAR
- Exhibit collq32026earningspresen.htm — COLLEGIUM PHARMACEUTICAL, INC 8-K exhibit — SEC EDGAR
- Collegium Pharmaceutical Q3 2026 Earnings Call Transcript — benzinga.com
- Collegium Reports Third Quarter 2026 Financial Results; — globenewswire.com